Market Overview

Citi Launches Positive Coverage On Five Prime Therapeutics

Citi Launches Positive Coverage On Five Prime Therapeutics
Related FPRX
10 Biggest Price Target Changes For Monday
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Citi’s Robyn Karnauskas believes Five Prime Therapeutics Inc (NASDAQ: FPRX) has a trifecta of factors in its favor, including its “hot” immunoncology (I/O) target, a solid partner in Bristol-Myers Squibb Co (NYSE: BMY) and strong platform technology.

Karnauskas initiated coverage of Five Prime with a Buy rating and price target of $65.

Multiple Catalysts

The analyst believes the company has “multiple shots on goal in various cancers,” as well as a promising lead drug in Cabiralizumab, compelling data from FPA144 in gastric cancer, which provides valuation support and “unique platform technology validated by multiple collaborations.”

Related Link: JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends

Karnauskas said as combo data with Opdivo becomes available for Cabira in 2017, investors would be able to assign a higher value to the program and there could be potential upside of 35–65 percent to the stock valuation.

Cabira Potential

“All major I/O developers are testing checkpoint combos with CSF-1R and those data should also help validate mechanism” for Cabira, the analyst pointed out.

Karnauskas expects Cabira to achieve peak sales of $800 million, with upside due to the I/O opportunity.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for FPRX

Sep 2018Leerink SwannReinstatesOutperform
Aug 2018CitigroupMaintainsBuyBuy
Aug 2018WedbushMaintainsNeutralNeutral

View More Analyst Ratings for FPRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (BMY + FPRX)

View Comments and Join the Discussion!

Citing Rising Risk Of Default, Argus Downgrades Tidewater To Sell

Live Cattle Futures Little Higher